These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3259617)

  • 21. Study on MPTP-induced parkinsonian animal model in rhesus monkey and the mechanism of MPTP.
    Chen SD; Xu DL; Yu HZ; Tang QM; Xu XR; Wang ZG; Liang PF
    Chin Med J (Engl); 1988 Dec; 101(12):879-83. PubMed ID: 3150735
    [No Abstract]   [Full Text] [Related]  

  • 22. Changes in the local cerebral metabolic rate for glucose in the MPTP primate model of Parkinson's disease.
    Schwartzman RJ; Alexander GM
    Adv Neurol; 1987; 45():171-3. PubMed ID: 3493624
    [No Abstract]   [Full Text] [Related]  

  • 23. The clinical syndrome of striatal dopamine deficiency: parkinsonism induced by MPTP.
    Eldridge R; Rocca WA
    N Engl J Med; 1985 Oct; 313(18):1159-60. PubMed ID: 3876508
    [No Abstract]   [Full Text] [Related]  

  • 24. Secondary (toxic) parkinsonism as model of Parkinson's disease.
    Riederer P; Sofic E; Heuschneider G; Benedetti MS; Dostert P
    Funct Neurol; 1988; 3(4):449-57. PubMed ID: 3072280
    [No Abstract]   [Full Text] [Related]  

  • 25. The MPTP story: MAO activates tetrahydropyridine derivatives to toxins causing parkinsonism.
    Maret G; Testa B; Jenner P; el Tayar N; Carrupt PA
    Drug Metab Rev; 1990; 22(4):291-332. PubMed ID: 2253555
    [No Abstract]   [Full Text] [Related]  

  • 26. Street drugs yield primate Parkinson's model.
    Blume E
    JAMA; 1983 Jul; 250(1):13-4. PubMed ID: 6602228
    [No Abstract]   [Full Text] [Related]  

  • 27. The MPTP story: an introduction.
    Marsden CD; Sandler M
    J Neural Transm Suppl; 1986; 20():1-3. PubMed ID: 3091759
    [No Abstract]   [Full Text] [Related]  

  • 28. Parkinson-like syndrome in nonhuman primates receiving a tetrahydropyridine derivative.
    Barsoum NJ; Gough AW; Sturgess JM; de la Iglesia FA
    Neurotoxicology; 1986; 7(1):119-26. PubMed ID: 3487056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A simple quantitative bradykinesia test in MPTP-treated mice.
    Ogawa N; Hirose Y; Ohara S; Ono T; Watanabe Y
    Res Commun Chem Pathol Pharmacol; 1985 Dec; 50(3):435-41. PubMed ID: 3878557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
    Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Leads from the MMWR. Street-drug contaminant causing parkinsonism.
    JAMA; 1984 Jul; 252(3):331. PubMed ID: 6610772
    [No Abstract]   [Full Text] [Related]  

  • 32. Endogenous analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: indoleamine derived tetrahydro-beta-carbolines as potential causative factors in Parkinson's disease.
    Collins MA; Neafsey EJ; Cheng BY; Hurley-Gius K; Ung-Chhun NA; Pronger DA; Christensen MA; Hurley-Gius D
    Adv Neurol; 1987; 45():179-82. PubMed ID: 3493625
    [No Abstract]   [Full Text] [Related]  

  • 33. [Parkinsonism and MPTP (methylphenyltetrahydropyridine)].
    Nagatsu T
    No To Shinkei; 1986 Jul; 38(7):706-7. PubMed ID: 3489476
    [No Abstract]   [Full Text] [Related]  

  • 34. [The neurotoxic effect of MPTP and its mechanisms].
    Xu XJ
    Sheng Li Ke Xue Jin Zhan; 1988 Oct; 19(4):310-4. PubMed ID: 3074503
    [No Abstract]   [Full Text] [Related]  

  • 35. Production in nature of compound resembling methylphenyltetrahydropyridine, a possible cause of Parkinson's disease.
    Ramsden DB; Williams AC
    Lancet; 1985 Jan; 1(8422):215-6. PubMed ID: 2857280
    [No Abstract]   [Full Text] [Related]  

  • 36. MPTP toxicity: clinical features.
    Williams A
    J Neural Transm Suppl; 1986; 20():5-9. PubMed ID: 3489070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MPTP: current concepts and controversies.
    Langston JW; Irwin I
    Clin Neuropharmacol; 1986; 9(6):485-507. PubMed ID: 3542203
    [No Abstract]   [Full Text] [Related]  

  • 38. MPTP-induced parkinsonism. Recent studies on the mechanism of toxicity.
    Bocchetta A; Piccardi MP; Zuddas A; Bernardi F; Zompo MD; Corsini GU
    Funct Neurol; 1988; 3(4):439-47. PubMed ID: 3072279
    [No Abstract]   [Full Text] [Related]  

  • 39. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model.
    Kim NK; Choi BH; Huang X; Snyder BJ; Bukhari S; Kong TH; Park H; Park HC; Park SR; Ha Y
    Eur J Neurosci; 2009 Mar; 29(5):891-900. PubMed ID: 19245369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.